Loading
Life sciences · Journal article
World Journal of Cardiology · October 13, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Heart failure with preserved ejection fraction (HFpEF) is a heterogeneous syndrome, with obesity defining an increasingly treatable cardiometabolic phenotype.Building on recent work identifying dysfunctional adiposity as an upstream contributor, this minireview focuses on the complementary question of how failure of safe lipid storage redirects substrate across visceral, hepatic, skeletal muscle, epicardial, perivascular, and myocardial compartments, and how this depot-specific routing intersects with myocardial metabolic inflexibility.Human imaging, invasive physiology, myocardial metabolomics, and recent clinical trials support associations between ectopic adiposity, insulin resistance, inflammation, impaired vascular and atrial reserve, congestion, and exercise intolerance, although causal pathways remain incompletely established in humans.We therefore propose an adiposity-aware, hypothesis-generating framework integrating body composition, regional adipose depots, metabolic-inflammatory biomarkers, atrial and right-sided function, and exercise assessment for phenotypeenriched research and future trial design.This framework is not intended to guide current treatment selection.Established treatment should remain evidence based, including exercise, sodium-glucose cotransporter 2 inhibition, mineralocorticoid receptor antagonism, decongestion, and obesity-directed incretin therapy, with attention to leanmass preservation.Future prospective studies should investigate whether depot quality, metabolic flexibility, sex and ethnic heterogeneity, and body composition provide additional information for phenotypic characterization and risk stratification beyond conventional measures.